Non disponible en dehors du Royaume-Uni et de l'Irlande
Biochem/physiol Actions
Primary TargetNMDA receptors
General description
A highly potent competitive antagonist selective for NMDA receptors (Ki = 35 nM). Biologically viable admitted orally or systematically. Widely used in studies of epilepsy, schizophrenia, depression, stress and anxiety related mental disorders.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Serafini, G., et al. 2013. Curr. Pharmaceut. Design19, 1898. Szewczyk, B., et al. 2012. Expert. Op. Invest. Drugs21, 91.Przegalinski, E., et al. 2000. Neuropharmacol.39, 1858. Maj, J., et al. 1993. Polish J. Pharmacol.45, 455.Fagg, E., et al. 1990. Br. J. Pharmacol.99, 791.Schmutz, M., et al. 1990. Naunyn-Schmiedeberg's Arch. Pharmacol.342, 61.
Preparation Note
Slight warming is required for complete solubilization.
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Warning
Toxicity: Standard Handling (A)
Ce produit répond aux critères suivants pour être admissible aux récompenses suivantes :